• Recruiting

NCT04521335: Phase 1: Study of Disulfiram and Copper Gluconate in Patients With RRMM (Repurpose-1)

Updated: Sep 2


(Repurpose-1)

NCT04521335: Phase 1: Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma (Repurpose-1)


disulfiram


This is a phase I, open-label trial of disulfiram in combination with copper gluconate in patients with treatment-refractory multiple myeloma. The trial is designed to assess the Phase 2 Recommended Dose (RP2D) of disulfiram and copper gluconate in combination. The trial will open with dose escalation, followed to an expansion cohort to further characterize the safety and tolerance of the combination.


Sponsor

University of Utah


Collaborator

Cantex Pharmaceuticals

 

ClinicalTrials.gov Identifier: NCT04521335

Official Title: A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

First Posted : August 20, 2020

Click here for details on ClinicalTrials.gov

 

Disulfiram

Disulfiram (Code C447)

Antabuse

Bis(diethylthiocarbamoyl) Disulfide

Disulfiram

DISULFIRAM

disulfiram

DS

Tetraethylthioperoxydicarbonic Diamide

Tetraethylthiuram Disulfide

Teturamin

TTD


Copper Gluconate

Copper Gluconate (Code C80050)

Copper Gluconate

COPPER GLUCONATE

Cupric Gluconate

 

Drug: Disulfiram

Drug: Copper Gluconate

 

Location

United States, Utah





Posts Archive